Davis Polk advised the representatives of the several underwriters in the offering. Century Therapeutics, Inc. executed the $242.7 million initial public offering of 12,132,500 shares of...
Century Therapeutics’ $242.7 Million Initial Public Offering
Cyteir’s $133.2 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in the IPO. Cyteir Therapeutics, Inc. executed the $133.2 million initial public offering of 7,400,000 shares of common...
RAPT Therapeutics’ $143.7 Million Equity Offering
Cooley advised RAPT Therapeutics, while Davis Polk advised the joint book-running managers in the offering. with a $143.7 million SEC-registered follow-on offering of 4,356,060 shares of...
Molecular Partners’ $63.8 Million Initial Public Offering in The US and Listing on NASDAQ Close
Homburger advised Molecular Partners AG in the transaction, while Davis Polk and Advestra advised the joint book-running managers and representatives of the underwriters. Molecular Partners AG,...
Post Holdings’ $85 Million Acquisition of TreeHouse Foods’ Ready-to-Eat Cereal Business
Winston & Strawn represented TreeHouse Foods in the transaction. TreeHouse Foods (NYSE: THS) closed its definitive agreement and completed sale of its ready-to-eat (RTE) cereal business to...
AgileThought’s $482 Million Business Combination With LIV Capital Acquisition Corp.
Davis Polk advised LIV Capital Acquisition Corp. on the deal. LIV Capital Acquisition Corp. (“LIVK”), a special purpose acquisition company, executed its approximately $482 million business...
ImmunityBio’s $500 Million At-the-Market Offering
Davis Polk advised the sales agent on the offering. ImmunityBio, Inc. executed an at-the-market offering of its common stock for up to an aggregate amount of $500 million....
ImmunityBio’s $500 Million At-the-Market Offering
Davis Polk advised the sales agent on the offering. ImmunityBio, Inc. executed an at-the-market offering of its common stock for up to an aggregate amount of $500 million....
Roivant Sciences Ltd.’s Merger with Montes Archimedes Acquisition Corp.
Conyers and Davis Polk & Wardwell is advising Roivant Sciences Ltd., in its business combination by merger of a subsidiary with Montes Archimedes Acquisition Corp. (MAAC)...
Vaccitech’s $110.5 Million Initial Public Offering
Goodwin Procter LLP advised Vaccitech on the deal, while Davis Polk advised the representatives of the several underwriters. Vaccitech (Nasdaq: VACC) announced its initial public offering...
NeuroPace’s $102 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in the offering. NeuroPace, Inc. executed its initial public offering of 6,900,000 shares of common stock at...
Akoya Biosciences’ $151.3 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in the offering. Akoya Biosciences, Inc. executed its $151.3 million initial public offering of 7,567,000 shares of common...